IPP Bureau

Touchlight & NEB launch game-changing benchtop DNA kit
Touchlight & NEB launch game-changing benchtop DNA kit

By IPP Bureau - March 20, 2026

This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development

MedRabbits launches integrated clinic to revolutionize patient care
MedRabbits launches integrated clinic to revolutionize patient care

By IPP Bureau - March 20, 2026

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals
Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

By IPP Bureau - March 20, 2026

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech

By IPP Bureau - March 20, 2026

The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology

Roche breaks lab barriers as FDA clears mass spec tests for wider use
Roche breaks lab barriers as FDA clears mass spec tests for wider use

By IPP Bureau - March 20, 2026

The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio

SK bioscience bags fresh backing to accelerate fight against respiratory disease
SK bioscience bags fresh backing to accelerate fight against respiratory disease

By IPP Bureau - March 20, 2026

RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute

NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future

By IPP Bureau - March 20, 2026

The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI
Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

By IPP Bureau - March 20, 2026

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients
Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients

By IPP Bureau - March 20, 2026

India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease

Glenmark Therapeutics USA launches fluticasone propionate nasal spray
Glenmark Therapeutics USA launches fluticasone propionate nasal spray

By IPP Bureau - March 20, 2026

The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million

Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets
Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets

By IPP Bureau - March 20, 2026

Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg

Epigenica expands into Japan via PrimeTech partnership
Epigenica expands into Japan via PrimeTech partnership

By IPP Bureau - March 20, 2026

The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial
Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

By IPP Bureau - March 20, 2026

LANXESS marks 40 yrs of animal disease defense 'Virkon S'
LANXESS marks 40 yrs of animal disease defense 'Virkon S'

By IPP Bureau - March 20, 2026

A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone

Clariant boosts US pharmaceutical production with Clear Lake expansion
Clariant boosts US pharmaceutical production with Clear Lake expansion

By IPP Bureau - March 20, 2026

The Clear Lake facility marks Clariant’s first U.S. site dedicated to PEG excipient production

Latest Stories

Interviews

Packaging